JPS6313224Y2 - - Google Patents

Info

Publication number
JPS6313224Y2
JPS6313224Y2 JP1983126908U JP12690883U JPS6313224Y2 JP S6313224 Y2 JPS6313224 Y2 JP S6313224Y2 JP 1983126908 U JP1983126908 U JP 1983126908U JP 12690883 U JP12690883 U JP 12690883U JP S6313224 Y2 JPS6313224 Y2 JP S6313224Y2
Authority
JP
Japan
Prior art keywords
parts
poultice
drug
layer
adhesive layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP1983126908U
Other languages
Japanese (ja)
Other versions
JPS6034822U (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to JP12690883U priority Critical patent/JPS6034822U/en
Publication of JPS6034822U publication Critical patent/JPS6034822U/en
Application granted granted Critical
Publication of JPS6313224Y2 publication Critical patent/JPS6313224Y2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)

Description

【考案の詳細な説明】 従来パツプ剤は織布、不織布等の面にカオリ
ン、ベントナイト等の基材にソルビトール、グリ
セリン、プロピレングリコール、アルカリ土類金
属塩等の湿潤剤、サリチル酸メチル、ハツカ油、
メントール、チモール、カンフル等の薬剤その他
の所要材料を配合したパツプ剤層を設けている。
これらパツプ剤の効果は配合薬剤の鎮痛、消炎作
用と水による冷却作用によつて発揮されるものと
考えられている。このためパツプ剤は薬剤の放出
性及び水による冷却性の改善と共にパツプ剤の密
着性の付与に関する種々の工夫がなされている
が、従来のパツプ剤の如く水を含有する系では、
パツプ剤層の接着力と凝集力(剥離時にパツプ剤
が皮膚に残留しないための凝集力)との調整が困
難で、その釣合いの良いものが得がたいほか、水
に対し不安定なサリチル酸エステル系薬剤は経時
変化の問題がある等の不利があつた。
[Detailed description of the invention] Conventional bulges have been prepared by adding a base material such as kaolin or bentonite to the surface of a woven or non-woven fabric, a wetting agent such as sorbitol, glycerin, propylene glycol, or an alkaline earth metal salt, methyl salicylate, peppermint oil, or the like.
A poultice layer containing drugs such as menthol, thymol, camphor, and other necessary materials is provided.
The effects of these poultices are thought to be exerted by the analgesic and anti-inflammatory effects of the combined drugs and the cooling effect of water. For this reason, various efforts have been made to improve the drug release properties and water-based cooling properties of poultices, as well as to provide adhesiveness to the poultices.However, in systems containing water such as conventional poultices,
It is difficult to adjust the adhesion and cohesive force of the poultice layer (the cohesive force that prevents the poultice from remaining on the skin when peeled off), and it is difficult to obtain a well-balanced product. In addition, salicylic acid ester drugs are unstable in water. However, there were disadvantages such as the problem of deterioration over time.

本案は皮膚に対する貼着作用と鎮痛消炎作用を
する薬剤含有粘着剤層と冷却作用をする含水ゲル
化物を有する複合体に形成したもので、薬剤の放
出性、患部に対する冷却性、皮膚との密着性等の
極めて良好なものを提供しようとするものであ
る。
This product is formed into a composite material that has a drug-containing adhesive layer that has adhesion to the skin and analgesic and anti-inflammatory effects, and a hydrous gel that has a cooling effect. The aim is to provide extremely good quality and quality.

以下実施例について説明すると、粘着剤に対し
剥離性を有するシート材1の剥離性な面に薬剤入
り粘着剤層2を設け、該粘着剤層の上面にゼラチ
ン、カゼイン等の蛋白質系含水ゲル化物層4を設
けてパツプ剤を形成している。
To explain an example below, a drug-containing adhesive layer 2 is provided on the releasable surface of a sheet material 1 that is releasable to an adhesive, and a protein-based hydrogel such as gelatin or casein is provided on the upper surface of the adhesive layer. A layer 4 is provided to form a poultice.

上記の含水ゲル化物にはゼラチン、カゼイン、
等の蛋白質をゲル化したものがあり、これらゲル
化物には、必要に応じてカオリン、ベントナイ
ト、炭酸カルシウム、その他の無機物質粉末、プ
ロピレングリコール、ソルビトール、グリセリ
ン、塩化マグネシウムその他の吸湿性物質、チモ
ールその他の防腐剤、その他従来のパツプ剤層に
使用されている各種物質の適宜量が配合できる。
上記の含水ゲル化物質を形成する原料配合剤を示
すと、ゼラチン12部(重量以下同様)、グリセリ
ン55部、炭酸カルシウム18部、酸化チタン5部、
塩化マグネシウム2.5部、サンウエツト1M300(三
洋化成KK商品名)0.5部、ポリアクリル酸ソーダ
4部、流動パラフイン2部、ツイン80(花王アト
ラスKK商品名)1部、グルタールアルデヒド0.1
部、チモール0.5部、精製水99.4部があり、上記
配合材料を適当に混合し、これを例えば約800
g/m2の割で前記粘着剤層上に塗布、冷却、固
化、含水ゲル状となし、これを更に1週間放置し
て安定化した含水ゲル化物質が形成できる。
The above hydrogelated products include gelatin, casein,
These gels may contain kaolin, bentonite, calcium carbonate, other inorganic substance powders, propylene glycol, sorbitol, glycerin, magnesium chloride and other hygroscopic substances, thymol, etc., as necessary. Appropriate amounts of other preservatives and other various substances used in conventional poultice layers can be added.
The raw materials used to form the above-mentioned water-containing gelatinized substance include 12 parts of gelatin (the same applies below weight), 55 parts of glycerin, 18 parts of calcium carbonate, 5 parts of titanium oxide,
2.5 parts of magnesium chloride, 0.5 parts of Sunwet 1M300 (Sanyo Kasei KK brand name), 4 parts of sodium polyacrylate, 2 parts of liquid paraffin, 1 part of Twin 80 (Kao Atlas KK brand name), 0.1 part of glutaraldehyde.
1 part, 0.5 parts of thymol, and 99.4 parts of purified water.
g/m 2 on the pressure-sensitive adhesive layer, cooled, solidified, and formed into a hydrogel, and left for another week to form a stabilized hydrogel.

前記薬剤には、サリチル酸メチル、サリチル酸
グリコール、メントール、カンフアー、ボルネオ
ール、ノニル酸ワニリルアミド、ハツカ油、トウ
ガラシエキス、ベラドンナエキス、ロートエキ
ス、ジフエンヒドラミンその他の消炎、鎮痛、刺
戟等の効果を有する物質があり、薬剤を配合する
粘着剤はゴム系、アクリル系、ビニルエーテル
系、シリコーン系等があり、目的に応じて適宜使
用できる。又上記剥離性シート材1にはシリコー
ン、高級脂肪酸等で処理した紙のほか、必要に応
じて前記剥離剤で処理したポリエチレン積層紙、
ポリエチレン、ポリプロピレン、ポリエステル、
アルミニウム箔積層ポリエチレンその他のプラス
チツクフイルムがある。
The drugs include methyl salicylate, glycol salicylate, menthol, camphor, borneol, nonylic acid vanillylamide, pepper oil, capsicum extract, belladonna extract, rotisserie extract, diphenhydramine, and other substances that have anti-inflammatory, analgesic, and stimulant effects. There are various types of adhesives that contain chemicals, such as rubber-based, acrylic-based, vinyl ether-based, and silicone-based adhesives, which can be used as appropriate depending on the purpose. In addition to paper treated with silicone, higher fatty acids, etc., the releasable sheet material 1 may also include polyethylene laminated paper treated with the above-mentioned release agent, if necessary.
polyethylene, polypropylene, polyester,
Aluminum foil laminated polyethylene and other plastic films are available.

上記の如く形成されたパツプ剤は所要大きさに
して、その剥離性シート材を剥がしその薬剤入り
粘着剤層を介して患部に貼りつけて使用される。
このパツプ剤はそのままの大きさ若しくは所要の
大きさ例えば14×10cm角等に裁断等して、そのゲ
ル化物質の上面をポリエチレンその他のフイルム
で被覆若しくは被覆せず、その適宜数、例えば5
枚をアルミニウム箔積層フイルム製等の袋に密封
して市場に供給する。
The poultice formed as described above is used by cutting it into a required size, peeling off the releasable sheet material, and pasting it on the affected area via the drug-containing adhesive layer.
This poultice can be used as it is or cut into pieces of the required size, e.g. 14 x 10 cm square, and the upper surface of the gelled substance may or may not be covered with polyethylene or other film, and the appropriate number of films, e.g.
The sheets are sealed in bags made of aluminum foil laminated film and supplied to the market.

本案は上述の如く構成されているので、患部皮
膚面との接着は粘着テープ並みの接着力(対ベー
クライト接着力約300g/30mm)で強固に付着で
きると共に薬剤は患部に近接してその作用も顕著
になり、小量の薬剤の使用ですぐれた効果が得ら
れる上薬剤は水分に分散することがないので、加
水分解も起らずサリチル酸エステル系薬剤も使用
でき、含水ゲル化物層による冷却作用と相俟つて
極めて大なる治療効果を奏する。
Since the present invention is constructed as described above, it can be firmly attached to the affected skin surface with an adhesive force comparable to that of adhesive tape (adhesive force to Bakelite of about 300 g/30 mm), and the drug can be placed close to the affected area and its effect can be maintained. In addition, since the drug does not disperse in water, no hydrolysis occurs, and salicylic acid ester drugs can also be used, and the cooling effect due to the hydrous gel layer Together with this, it has an extremely large therapeutic effect.

【図面の簡単な説明】[Brief explanation of the drawing]

図面は本案の実施例を示し、第1図は斜面図、
第2図は断面図。 1は剥離性シート材、2は薬剤含有粘着剤層、
4は含水ゲル化物層。
The drawings show an example of the present invention, and Figure 1 is a slope view;
Figure 2 is a sectional view. 1 is a removable sheet material, 2 is a drug-containing adhesive layer,
4 is a hydrous gelled material layer.

Claims (1)

【実用新案登録請求の範囲】[Scope of utility model registration request] 薬剤含有粘着剤層の上にゼラチン、カゼイン等
の蛋白質系含水ゲル化物層を形成したパツプ剤。
A poultice with a hydrogelled protein layer such as gelatin or casein formed on a drug-containing adhesive layer.
JP12690883U 1983-08-18 1983-08-18 poultice Granted JPS6034822U (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP12690883U JPS6034822U (en) 1983-08-18 1983-08-18 poultice

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP12690883U JPS6034822U (en) 1983-08-18 1983-08-18 poultice

Publications (2)

Publication Number Publication Date
JPS6034822U JPS6034822U (en) 1985-03-09
JPS6313224Y2 true JPS6313224Y2 (en) 1988-04-14

Family

ID=30288412

Family Applications (1)

Application Number Title Priority Date Filing Date
JP12690883U Granted JPS6034822U (en) 1983-08-18 1983-08-18 poultice

Country Status (1)

Country Link
JP (1) JPS6034822U (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6148081B2 (en) * 2013-06-18 2017-06-14 日本電子精機株式会社 A patch for covering a curved surface and / or an uneven portion of the body

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55129056A (en) * 1979-03-26 1980-10-06 Nitto Electric Ind Co Poultice

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55129056A (en) * 1979-03-26 1980-10-06 Nitto Electric Ind Co Poultice

Also Published As

Publication number Publication date
JPS6034822U (en) 1985-03-09

Similar Documents

Publication Publication Date Title
JP3335569B2 (en) Sheet-shaped pack package and manufacturing method thereof
US5008110A (en) Storage-stable transdermal patch
AU603531B2 (en) Device for administering an active agent to the skin or mucosa
JP2527547B2 (en) Therapeutic device for drug administration
ES2224102T3 (en) NON-OCLUSIVE ADHESIVE PATCH TO APPLY SKIN MEDICATION.
EP0356614B1 (en) Dermal applicator
US5064422A (en) Twin patch applicator
KR100267442B1 (en) Transdermally administered system containing acetylsalicylic acid for thrombosis therapy and cancer prophylaxis
JP2000517343A (en) Pressure sensitive adhesive matrix patch for transdermal delivery of pharmaceutical salts
JPS60168450A (en) Bandage
JP4139689B2 (en) Packaging system for transdermal drug delivery system
US4788064A (en) Transdermal delivery system
JPS6324959A (en) Partitioned percutaneous delivery system
JPS6313224Y2 (en)
WO2005084255A2 (en) Aspirin transdermal patch
FI120719B (en) A process for the preparation of a transdermal system containing acetylsalicylic acid
JP2781016B2 (en) Transdermal formulation
JPH09299445A (en) Packed body for plaster agent containing medicine
JPS63200760A (en) Production of sheet like adhesive
JP2882650B2 (en) Semi-solid drug applicator
JPH0754259Y2 (en) Skin patch
JPH0711131Y2 (en) External patch
JPH0538011Y2 (en)
JP4327958B2 (en) Cooling patch
JPH0357251Y2 (en)